This book on cardiac extracellular matrix (ECM) features three sections,
Fundamental Science, Pre-Clinical and Translational Science, and
Clinical Applications. In the Fundamental Science section, we will cover the spectrum of basic ECM science from ECM’s role in development, biomechanical properties, cardiac ECM influence of cardiomyocyte biology, pathophysiology of ECM in heart disease, and ECM in tissue engineering. Section two, Preclinical and Translational Science, will discuss cardiac ECM technologies in the clinical pipeline including approaches to ECM as a therapeutic, animal models of cardiac research, tracking and imaging methods of cardiac ECM, and cGMP manufacturing and regulatory considerations for ECM based therapeutics. Finally, the third section, Clinical Applications, will highlight the clinical experience around cardiac ECM including therapeutic strategies targeting scar tissue in the heart, Clinical trial design and regulatory considerations, current human clinical trials in cardiovascular medicine and the role of pharmaceutical and biotech companies in the commercialization of ECM technologies for cardiovascular indications. This book provides a comprehensive review for basic and translational researchers as well as clinical practitioners and those involved in commercialization, regulatory and entrepreneurial activities.
Eric Schmuck, PhD, is a Senior Scientist with the Division of Cardiovascular Medicine at the University of Wisconsin-Madison School of Medicine and Public Health where he leads multi-disciplinary research teams focused on bringing regenerative medicine therapies to the clinic. He received his PhD in Human Physiology from the University of Wisconsin-Madison and is an expert in cardiac extracellular matrix and translational research models, specifically focusing on cardiac regeneration. His major research interests are in cardiac extracellular matrix, bioengineering and regenerative medicine therapies for the heart. He has authored numerous peer-reviewed manuscripts and book chapters in the regenerative medicine field and holds multiple patents on cardiac extracellular matrix technologies. Finally, he is a co-founder and Chief Scientific Officer of Cellular Logistics Inc., a biotech company developing innovative biomaterial solutions to enhance stem cell retention for the treatment of advanced cardiovascular disease.
Peiman Hematti, MD is Professor of Medicine in section of Hematology/Oncology, UW-Madison School of Medicine and Public Health, with joint appointments in departments of pediatrics, surgery and biomedical engineering. He is director of Clinical Hematopoietic Cell Processing Laboratory, and medical director of Apheresis and Hematopoietic Cell Collection facility at University of Wisconsin-Madison. As a bone marrow stem cell transplant physician, his major clinical research interest is in immunology of transplantation and use of novel cellular therapies for malignant and non-malignant disorders, including use of bone marrow stem cells in cardiovascular medicine. His current laboratory research focuses on immunobiology of stem cell transplantation with a special focus on investigating the immunomodulatory and anti-inflammatory properties of macrophages, including their interactions with biomaterials used in regenerative medicine. He has been a co-author in more than 100 peer-reviewed manuscripts, 10 book chapters, and has been co-editor of two other books in the field of stem cells and regenerative medicine. He has been inventor of several patents issued and filed in the field of cellular therapy and regenerative medicine. He is a co-founder and chair of the Scientific Advisory Board for Cellular Logistics Inc.
Amish N. Raval MD is an Associate Professor of Medicine and Biomedical Engineering at the University of Wisconsin. He received his MD at the U. of Western Ontario, where he completed Internal Medicine and Cardiology Residency. He subsequently completed his Interventional Cardiology Fellowship at Georgetown University/Washington Hospital Center, and later, he joined the National Heart, Lung and Blood Institute, Bethesda. Thereafter, he became a Faculty member at the University of Wisconsin School of Medicine and Public Health where he is Di^12 cardiovascular regenerative medicine clinical trials ranging from Phase 1 to 3. He has served as a scientific advisor for several biotech companies and is Chairman of the Board for Cellular Logistics Inc, which is a biotech company that is developing innovative biomaterial solutions to enhance stem cell retention for the treatment of advanced cardiovascular disease.
